Publication

Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study

Bergman, J. E. H., Lutke, L. R., Gans, R. O. B., Addor, M-C., Barisic, I., Cavero-Carbonell, C., Garne, E., Gatt, M., Klungsoyr, K., Lelong, N., Lynch, C., Mokoroa, O., Nelen, V., Neville, A. J., Pierini, A., Randrianaivo, H., Rissmann, A., Tucker, D., Wiesel, A., Dolk, H., Loane, M. & Bakker, M. K., Apr-2018, In : Drug Safety. 41, 4, p. 415-427 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Bergman, J. E. H., Lutke, L. R., Gans, R. O. B., Addor, M-C., Barisic, I., Cavero-Carbonell, C., Garne, E., Gatt, M., Klungsoyr, K., Lelong, N., Lynch, C., Mokoroa, O., Nelen, V., Neville, A. J., Pierini, A., Randrianaivo, H., Rissmann, A., Tucker, D., Wiesel, A., ... Bakker, M. K. (2018). Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study. Drug Safety, 41(4), 415-427. https://doi.org/10.1007/s40264-017-0627-x

Author

Bergman, Jorieke E H ; Lutke, L Renée ; Gans, Rijk O B ; Addor, Marie-Claude ; Barisic, Ingeborg ; Cavero-Carbonell, Clara ; Garne, Ester ; Gatt, Miriam ; Klungsoyr, Kari ; Lelong, Nathalie ; Lynch, Catherine ; Mokoroa, Olatz ; Nelen, Vera ; Neville, Amanda J ; Pierini, Anna ; Randrianaivo, Hanitra ; Rissmann, Anke ; Tucker, David ; Wiesel, Awi ; Dolk, Helen ; Loane, Maria ; Bakker, Marian K. / Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies : A European Case-Malformed Control Study. In: Drug Safety. 2018 ; Vol. 41, No. 4. pp. 415-427.

Harvard

Bergman, JEH, Lutke, LR, Gans, ROB, Addor, M-C, Barisic, I, Cavero-Carbonell, C, Garne, E, Gatt, M, Klungsoyr, K, Lelong, N, Lynch, C, Mokoroa, O, Nelen, V, Neville, AJ, Pierini, A, Randrianaivo, H, Rissmann, A, Tucker, D, Wiesel, A, Dolk, H, Loane, M & Bakker, MK 2018, 'Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study', Drug Safety, vol. 41, no. 4, pp. 415-427. https://doi.org/10.1007/s40264-017-0627-x

Standard

Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies : A European Case-Malformed Control Study. / Bergman, Jorieke E H; Lutke, L Renée; Gans, Rijk O B; Addor, Marie-Claude; Barisic, Ingeborg; Cavero-Carbonell, Clara; Garne, Ester; Gatt, Miriam; Klungsoyr, Kari; Lelong, Nathalie; Lynch, Catherine; Mokoroa, Olatz; Nelen, Vera; Neville, Amanda J; Pierini, Anna; Randrianaivo, Hanitra; Rissmann, Anke; Tucker, David; Wiesel, Awi; Dolk, Helen; Loane, Maria; Bakker, Marian K.

In: Drug Safety, Vol. 41, No. 4, 04.2018, p. 415-427.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Bergman JEH, Lutke LR, Gans ROB, Addor M-C, Barisic I, Cavero-Carbonell C et al. Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study. Drug Safety. 2018 Apr;41(4):415-427. https://doi.org/10.1007/s40264-017-0627-x


BibTeX

@article{37923560c0534bf09ac21ba4f3021a59,
title = "Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study",
abstract = "The prevalence of chronic hypertension is increasing in pregnant women. Beta-blockers are among the most prevalent anti-hypertensive agents used in early pregnancy.The objective of this study was to investigate whether first-trimester use of beta-blockers increases the risk of specific congenital anomalies in offspring.A population-based case-malformed control study was conducted in 117,122 registrations of congenital anomalies from 17 European Concerted Action on Congenital Anomalies and Twins (EUROCAT) registries participating in EUROmediCAT with data for all or part of the period between 1995 and 2013. Associations previously reported in the literature (signals) were tested and an exploratory analysis was performed to identify new signals. Odds ratios of exposure to any beta-blocker or to a beta-blocker subgroup were calculated for each signal anomaly compared with two control groups (non-chromosomal, non-signal anomalies and chromosomal anomalies). The exploratory analyses were performed for each non-signal anomaly compared with all the other non-signal anomalies.The signals from the literature (congenital heart defects, oral clefts, neural tube defects and hypospadias) were not confirmed. Our exploratory analysis revealed that multi-cystic renal dysplasia had significantly increased odds of occurring after maternal exposure to combined alpha- and beta-blockers (adjusted odds ratio 3.8; 95% confidence interval 1.3-11.0).Beta-blocker use in the first trimester of pregnancy was not found to be associated with a higher risk of specific congenital anomalies in the offspring, but a new signal between alpha- and beta-blockers and multi-cystic renal dysplasia was found. Future large epidemiological studies are needed to confirm or refute our findings.",
keywords = "ANTIHYPERTENSIVE MEDICATION USE, CONVERTING ENZYME-INHIBITORS, HYPERTENSIVE DISORDERS, MATERNAL HYPERTENSION, BIRTH-DEFECTS, DRUGS, MALFORMATIONS, PRESCRIPTION, HYPOSPADIAS, POPULATION",
author = "Bergman, {Jorieke E H} and Lutke, {L Ren{\'e}e} and Gans, {Rijk O B} and Marie-Claude Addor and Ingeborg Barisic and Clara Cavero-Carbonell and Ester Garne and Miriam Gatt and Kari Klungsoyr and Nathalie Lelong and Catherine Lynch and Olatz Mokoroa and Vera Nelen and Neville, {Amanda J} and Anna Pierini and Hanitra Randrianaivo and Anke Rissmann and David Tucker and Awi Wiesel and Helen Dolk and Maria Loane and Bakker, {Marian K}",
year = "2018",
month = apr,
doi = "10.1007/s40264-017-0627-x",
language = "English",
volume = "41",
pages = "415--427",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "ADIS INT LTD",
number = "4",

}

RIS

TY - JOUR

T1 - Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies

T2 - A European Case-Malformed Control Study

AU - Bergman, Jorieke E H

AU - Lutke, L Renée

AU - Gans, Rijk O B

AU - Addor, Marie-Claude

AU - Barisic, Ingeborg

AU - Cavero-Carbonell, Clara

AU - Garne, Ester

AU - Gatt, Miriam

AU - Klungsoyr, Kari

AU - Lelong, Nathalie

AU - Lynch, Catherine

AU - Mokoroa, Olatz

AU - Nelen, Vera

AU - Neville, Amanda J

AU - Pierini, Anna

AU - Randrianaivo, Hanitra

AU - Rissmann, Anke

AU - Tucker, David

AU - Wiesel, Awi

AU - Dolk, Helen

AU - Loane, Maria

AU - Bakker, Marian K

PY - 2018/4

Y1 - 2018/4

N2 - The prevalence of chronic hypertension is increasing in pregnant women. Beta-blockers are among the most prevalent anti-hypertensive agents used in early pregnancy.The objective of this study was to investigate whether first-trimester use of beta-blockers increases the risk of specific congenital anomalies in offspring.A population-based case-malformed control study was conducted in 117,122 registrations of congenital anomalies from 17 European Concerted Action on Congenital Anomalies and Twins (EUROCAT) registries participating in EUROmediCAT with data for all or part of the period between 1995 and 2013. Associations previously reported in the literature (signals) were tested and an exploratory analysis was performed to identify new signals. Odds ratios of exposure to any beta-blocker or to a beta-blocker subgroup were calculated for each signal anomaly compared with two control groups (non-chromosomal, non-signal anomalies and chromosomal anomalies). The exploratory analyses were performed for each non-signal anomaly compared with all the other non-signal anomalies.The signals from the literature (congenital heart defects, oral clefts, neural tube defects and hypospadias) were not confirmed. Our exploratory analysis revealed that multi-cystic renal dysplasia had significantly increased odds of occurring after maternal exposure to combined alpha- and beta-blockers (adjusted odds ratio 3.8; 95% confidence interval 1.3-11.0).Beta-blocker use in the first trimester of pregnancy was not found to be associated with a higher risk of specific congenital anomalies in the offspring, but a new signal between alpha- and beta-blockers and multi-cystic renal dysplasia was found. Future large epidemiological studies are needed to confirm or refute our findings.

AB - The prevalence of chronic hypertension is increasing in pregnant women. Beta-blockers are among the most prevalent anti-hypertensive agents used in early pregnancy.The objective of this study was to investigate whether first-trimester use of beta-blockers increases the risk of specific congenital anomalies in offspring.A population-based case-malformed control study was conducted in 117,122 registrations of congenital anomalies from 17 European Concerted Action on Congenital Anomalies and Twins (EUROCAT) registries participating in EUROmediCAT with data for all or part of the period between 1995 and 2013. Associations previously reported in the literature (signals) were tested and an exploratory analysis was performed to identify new signals. Odds ratios of exposure to any beta-blocker or to a beta-blocker subgroup were calculated for each signal anomaly compared with two control groups (non-chromosomal, non-signal anomalies and chromosomal anomalies). The exploratory analyses were performed for each non-signal anomaly compared with all the other non-signal anomalies.The signals from the literature (congenital heart defects, oral clefts, neural tube defects and hypospadias) were not confirmed. Our exploratory analysis revealed that multi-cystic renal dysplasia had significantly increased odds of occurring after maternal exposure to combined alpha- and beta-blockers (adjusted odds ratio 3.8; 95% confidence interval 1.3-11.0).Beta-blocker use in the first trimester of pregnancy was not found to be associated with a higher risk of specific congenital anomalies in the offspring, but a new signal between alpha- and beta-blockers and multi-cystic renal dysplasia was found. Future large epidemiological studies are needed to confirm or refute our findings.

KW - ANTIHYPERTENSIVE MEDICATION USE

KW - CONVERTING ENZYME-INHIBITORS

KW - HYPERTENSIVE DISORDERS

KW - MATERNAL HYPERTENSION

KW - BIRTH-DEFECTS

KW - DRUGS

KW - MALFORMATIONS

KW - PRESCRIPTION

KW - HYPOSPADIAS

KW - POPULATION

U2 - 10.1007/s40264-017-0627-x

DO - 10.1007/s40264-017-0627-x

M3 - Article

C2 - 29230691

VL - 41

SP - 415

EP - 427

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -

ID: 51517160